INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ACH-1625 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C
NEW HAVEN, Conn., Jan. 4, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced today the receipt of a Fast Track designation from the U.S.
View HTML
Toggle Summary ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C
NEW HAVEN, Conn., May 15, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the receipt of a Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACH-3102 as part of an interferon-free regimen for the treatment of chronic hepatitis C
View HTML
Toggle Summary Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")
Achillion to Begin a Six Week Treatment Regimen With Its Second-Generation NS5A Inhibitor ACH-3102 and Sofosbuvir
View HTML
Toggle Summary Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102
- Achillion achieves 100% SVR12 in six-week regimen with combination of ACH-3102 and sofosbuvir for treatment-naïve genotype 1 HCV - - Achillion to initiate 4-week treatment regimens based on the strength of ACH-3102 antiviral data - NEW HAVEN, Conn., Feb.
View HTML
Toggle Summary Achillion Added to the NASDAQ Biotechnology Index (NBI)
NEW HAVEN, Conn., May 18, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced that the Company will be added to the NASDAQ Biotechnology Index®
View HTML
Toggle Summary Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV
- Dosing Initiated in Phase 1 Study to Evaluate the Safety, Tolerability and Antiviral Activity of ACH-3422, NS5B Uridine-Analog Nucleotide Prodrug - - Initiated Phase 2 Study Evaluating ACH-3102, Second-Generation NS5A Inhibitor, With Sofosbuvir for 8 Weeks of Treatment or Less in Genotype 1 HCV
View HTML
Toggle Summary Achillion Advances Second Generation Pan-Genotypic NS5A Inhibitor, ACH-3102, Into Clinical Development
Structurally Distinct NS5A Inhibitor Displays Potent Preclinical Activity Against Commonly Observed Resistant Variants
View HTML
Toggle Summary Achillion and FOB Synthesis Announce Collaboration for the Development of Carbapenem Compounds
NEW HAVEN, Conn. and KENNESAW, Ga., Apr 8, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) and FOB Synthesis, Inc. today announced that the companies have signed an exclusive agreement granting Achillion worldwide rights for the research, development
View HTML
Toggle Summary Achillion Announces Receipt of SBIR Grant from National Institutes of Health for New Area of HIV Research
Company to Optimize Novel Capsid Assembly Inhibitor
View HTML
Toggle Summary Achillion Announces 100% SVR Reported in Janssen's Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV
- New data released today in abstract for upcoming EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection — The Roadmap For Cure - - Janssen advancing triple combination into Phase 2b clinical trial - NEW HAVEN, Conn., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Achillion
View HTML